Statement of total voting rights and shares forming the company's share capital as of April 11, 2025

Article R. 22-10-23 of the French Commercial CodeMarket: Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site:www.inventivapharma.com DateNumber of shares outstandingTotal voting rights, gross(1) Total voting rights, net(2) April 11, 202595,662,391108,635,435108,574,827The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General...

DAIX, 30/04/2025 (informazione.news - comunicati stampa - salute e benessere)

Market: Euronext Paris
ISIN code / Mnemo: FR0013233012 / IVA
Web site: www.inventivapharma.com

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:
FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
http://www.inventivapharma.com

Attachment